New agents and new end points for recurrent gliomas

Journal of Clinical Oncology

Volumn 29, Issue 9, 2011, Pages

  Brandes, Alba A ^a   Franceschi, Enrico ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR;

BRAIN TUMOR; CONTRAST ENHANCEMENT; GLIOBLASTOMA; GLIOMA; LETTER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79952749187     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.2809     Document Type: Letter

References (9)

1. Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 28:1963-1972, 2010
2. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990 (Pubitemid 20195640)
3. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999 (Pubitemid 29368260)
4. Lamborn KR, Yung WK, Chang SM, et al: Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-170, 2008
5. Ballman KV, Buckner JC, Brown PD, et al: The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9:29-38, 2007 (Pubitemid 46543486)
6. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
7. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
8. Levin VA, Crafts DC, Norman DM, et al: Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 47:329-335, 1977 (Pubitemid 8170121)
9. Franceschi E, Brandes AA, Tosoni A, et al: Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? J Clin Oncol 28:51s, 2010 (suppl; abstr 2022)